Authors: U. Pratap; Z. Slavík; V. Ofoe; O. Onuzo; Franklin R. C. G.; J. Wray; R. Radley-Smith Authors‘ workplace: Paediatric Surgical Unit, Harefield Hospital, Royal Brompton and Harefield NHS Trust, Harefield, United Kingdom Published in: Čes-slov Pediat 2004; (12): 605-609. Category:
Experimental evidence shows that Cyclosporin A reduces traumatic and ischaemic/reperfusion injury to braintissue. Authors test the hypothesis that survivors treated by Cyclosporin A at the time of cardiac arrest will havebetter neurodevelopmental outcome. They reviewed retrospectively outcome of cardiopulmonary resuscitationbetween children with congenital or acquired heart disease, and children who underwent cardiac transplantationand were treated with Cyclosporin A in tertiary pediatric cardiac center between 1990-2001. Patients surviving to3 months following cardiac arrest lasting over 7 minutes were assessed using 2 neurodevelopmental scoring systems(Pediatric Overall, and Cerebral, Performance Category scales). There were 2 survivors from 69 non-transplantpatients (3%) and 8 survivors from 15 transplant patients (53%; p
Key words: reperfusion injury, neuroprotection, Cyclosporin A, heart transplantation
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
